{"id":"NCT01323660","sponsor":"GlaxoSmithKline","briefTitle":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B","officialTitle":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-16","primaryCompletion":"2012-07-01","completion":"2012-07-16","firstPosted":"2011-03-25","resultsPosted":"2014-04-11","lastUpdate":"2018-02-15"},"enrollment":307,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"GSK573719/GW642444 125/25","otherNames":[]},{"type":"DRUG","name":"GSK573719/GW642444 62.5/25","otherNames":[]},{"type":"DRUG","name":"GSK573719 125","otherNames":[]},{"type":"DRUG","name":"GSK573719 62.5","otherNames":[]},{"type":"DRUG","name":"GW642444 25","otherNames":[]},{"type":"DEVICE","name":"placebo","otherNames":[]}],"arms":[{"label":"GSK573719/GW642444 125/25","type":"EXPERIMENTAL"},{"label":"GSK573719/GW642444 62.5/25","type":"EXPERIMENTAL"},{"label":"GSK573719/ 125","type":"EXPERIMENTAL"},{"label":"GSK573719 62.5","type":"EXPERIMENTAL"},{"label":"GW642444 25","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).","primaryOutcome":{"measure":"Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period","timeFrame":"Week 12 of each treatment period (up to Study Week 30)","effectByArm":[{"arm":"Placebo","deltaMin":0.1,"sd":16.66},{"arm":"UMEC 62.5 µg QD","deltaMin":25.1,"sd":30.18},{"arm":"UMEC 125 µg QD","deltaMin":74.8,"sd":31.58},{"arm":"VI 25 µg QD","deltaMin":30.7,"sd":24.79},{"arm":"UMEC/VI 62.5/25 µg QD","deltaMin":69.5,"sd":17.09},{"arm":"UMEC/VI 125/25 µg QD","deltaMin":65.9,"sd":17.48}],"pValues":[{"comp":"OG000 vs OG001","p":"0.456"},{"comp":"OG000 vs OG002","p":"0.033"},{"comp":"OG000 vs OG003","p":"0.295"},{"comp":"OG001 vs OG004","p":"0.188"},{"comp":"OG003 vs OG004","p":"0.187"},{"comp":"OG002 vs OG005","p":"0.801"},{"comp":"OG003 vs OG005","p":"0.233"},{"comp":"OG000 vs OG004","p":"0.003"},{"comp":"OG000 vs OG005","p":"0.005"}]},"eligibility":{"minAge":"40 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":53,"countries":["United States","Canada","Czechia","Denmark","South Africa","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":151},"commonTop":["Nasopharyngitis","Headache","Cough","Sinusitis","Arthralgia"]}}